Hoechst Japan Limited

Other

Hoechst Pharmaceuticals & Chemicals K.k.

Hiroshi Watanabe

Masako Wagatsuma

Michio Kimrua

Fujio Takeuchi

Hiroshi Kitagawa

Hiroshi Okazaki

Kazuyuki Kitamura

Hans G Berscheid

Mikio Akita

Masaru Taniguchi

Nobuyuki Yamagata

Junko Usui

Toshiro Iwahashi

Akio Fukuda

Etsuko Ohkouchi

Yukiko Tone

Kohsei Gotoh

Isamu Sugawara

Hitoko Numata

Shunji Senda

Akihiko Matsuo

Itsuo Kurobane

A reagent for immunologically detecting rheumatism containing as an antigen at least one mammalian protein selected from among ezrin, radixin and moesin and/or a peptide composed of at least nine consecutive amino acid residues found in the amino acid sequences of ezrin, radixin and moesin; and a method of detecting autoantibodies present in the serum of a rheumatic. An immunological reaction using this reagent enables precritical or early diagnosis of rheumatism. An immunological detection using the above autoantigenic proteins is convenient and reliable as an early serodiagnostic method based on rheumatism-specific antigens.

Method of detecting autoantibody present in the serum of rheumatic

Method of treating diabetes mellitus using variable .alpha. domain of

An animal tissue antigen for osteoporotic patients that reacts with antibody in a serum of human osteoporotic patients, but does not react with that in normal human serum. Preferably, a specific antigen for osteoporotic patients in rat or mouse epithelium of tongue mucous membrane, epithelium of tracheal mucous membrane, upper lip epidermis or follicular epithelium containing upper lip hair shafts, or a specific antigen for osteoporotic patients contained in cultured cells of a human squamous cell tongue carcinoma cell lines such as SCC-9 and fibroblast cell lines such as MRC-5. Osteoporosis can be both specifically and easily diagnosed by bringing the above-mentioned antigen in contact with a serum of a subject and then testing for the presence of an antigen-antibody reaction.

Tissue antigen and diagnostic method for human osteoporosis using the

Cytorhodin S derivatives, especially cytorhodin S-immunoglobulin complexes are disclosed. Cytorhodin S possesses very high anticancer activity, but the complexes act more selectively on cancer cells and are more useful as an anticancer agent. New intermediate derivatives are also useful as an anticancer agent.

Cytorhodin S derivatives and a process for their preparation

Growing community of inventors

Saitama, Japan

Hiroshi Watanabe